Northland Securities Predicts TLSI FY2025 Earnings

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) – Equities researchers at Northland Securities issued their FY2025 earnings per share (EPS) estimates for TriSalus Life Sciences in a report released on Monday, March 2nd. Northland Securities analyst C. Byrnes anticipates that the company will earn ($0.85) per share for the year. The consensus estimate for TriSalus Life Sciences’ current full-year earnings is ($1.55) per share.

Several other research analysts also recently issued reports on the stock. Wall Street Zen downgraded shares of TriSalus Life Sciences from a “hold” rating to a “sell” rating in a research report on Sunday, February 8th. Weiss Ratings reiterated a “sell (e+)” rating on shares of TriSalus Life Sciences in a research note on Monday, December 29th. Canaccord Genuity Group raised their price target on TriSalus Life Sciences from $11.00 to $12.00 and gave the stock a “buy” rating in a report on Wednesday, December 17th. Finally, Zacks Research raised TriSalus Life Sciences from a “strong sell” rating to a “hold” rating in a research note on Tuesday, December 16th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, TriSalus Life Sciences has an average rating of “Hold” and a consensus price target of $12.00.

TriSalus Life Sciences Price Performance

Shares of TriSalus Life Sciences stock opened at $4.94 on Wednesday. The firm’s fifty day simple moving average is $5.50 and its 200-day simple moving average is $5.37. TriSalus Life Sciences has a 12 month low of $3.42 and a 12 month high of $7.95. The stock has a market capitalization of $247.30 million, a price-to-earnings ratio of -2.45 and a beta of 0.42.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Goldman Sachs Group Inc. acquired a new stake in TriSalus Life Sciences in the first quarter valued at about $187,000. Geode Capital Management LLC raised its stake in shares of TriSalus Life Sciences by 107.4% during the 2nd quarter. Geode Capital Management LLC now owns 455,051 shares of the company’s stock worth $2,480,000 after buying an additional 235,627 shares in the last quarter. Police & Firemen s Retirement System of New Jersey acquired a new stake in shares of TriSalus Life Sciences in the 2nd quarter valued at approximately $29,000. JPMorgan Chase & Co. lifted its holdings in shares of TriSalus Life Sciences by 35,804.8% in the 2nd quarter. JPMorgan Chase & Co. now owns 7,540 shares of the company’s stock valued at $41,000 after buying an additional 7,519 shares during the period. Finally, Connective Capital Management LLC boosted its stake in shares of TriSalus Life Sciences by 12.8% in the second quarter. Connective Capital Management LLC now owns 32,796 shares of the company’s stock valued at $179,000 after buying an additional 3,717 shares in the last quarter. 2.58% of the stock is currently owned by institutional investors and hedge funds.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.